Eli Lilly and Company
LLY.MX
| Exchange: | MX |
| Currency | Mexican Peso |
| Fiscal Year End: | December |
| Sector: | Healthcare |
| Industry: | Drug Manufacturers - General |
| Gic Sector: | Health Care |
| Gic Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| Gic Industry: | Pharmaceuticals |
| Gic Sub Industry: | Pharmaceuticals |
| Description: | Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., Ab Cellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QI Astat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana. |
| Address: | Lilly Corporate Center, Indianapolis, IN, United States, 46285 |
| Website: | https://www.lilly.com |
| Full Time Employees: | 43000 |
| Updated On: | 2024-11-04 |
Highlights
| Market Capitalization: | 15421637918720 |
| Market Capitalization Mln: | 15421637.91 |
| EBITDA: | 16566500352 |
| PE Ratio: | 86.89 |
| PEG Ratio: | 0.78 |
| Book Value: | 15.82 |
| Dividend Share: | 5.03 |
| Earnings Share: | 186.96 |
| Most Recent Quarter: | 2024-06-30 |
| Profit Margin: | 0.20 |
| Operating Margin TTM: | 0.39 |
| Return On Assets TTM: | 0.13 |
| Return On Equity TTM: | 0.65 |
| Revenue TTM: | 40863301632 |
| Revenue Per Share TTM: | 45.36 |
| Quarterly Revenue Growth YOY: | 0.20 |
| Gross Profit TTM: | 21911600000 |
| Diluted Eps TTM: | 186.96 |
| Quarterly Earnings Growth YOY: | 0.68 |
Valuation
| Trailing PE: | 86.89 |
| Forward PE: | 36.63 |
| Price Sales TTM: | 377.39 |
| Price Book MRQ: | 55.44 |
| Enterprise Value: | 16156115211868 |
| Enterprise Value Revenue: | 19.70 |
| Enterprise Value Ebitda: | 64.32 |
Shares
| Shares Outstanding: | 949315968 |
| Shares Float: | 897175323 |
| Percent Insiders: | 0.15 |
| Percent Institutions: | 83.73 |
Technicals
| Beta: | 0.41 |
| 52 Week High: | 19261 |
| 52 Week Low: | 9486.57 |
| 50 Day MA: | 17928.33 |
| 200 Day MA: | 15112.66 |
Splits & Dividends
| Forward Annual Dividend Rate: | 103.79 |
| Payout Ratio: | 0.62 |
| Ex Dividend Date: | 2024-11-15 |
Earnings
| Report Date: | 2025-10-28 |
| Date: | 2025-09-30 |
| Before After Market: | Before Market |
| Currency: | MXN |
| Report Date: | 2025-04-28 |
| Date: | 2025-03-31 |
| Before After Market: | Before Market |
| Currency: | MXN |
| Report Date: | 2025-02-04 |
| Date: | 2024-12-31 |
| Before After Market: | Before Market |
| Currency: | MXN |
| Report Date: | 2024-10-30 |
| Date: | 2024-09-30 |
| Before After Market: | Before Market |
| Currency: | MXN |
| Report Date: | 2024-08-08 |
| Date: | 2024-06-30 |
| Before After Market: | Before Market |
| Currency: | MXN |
| Eps Actual: | 56.61 |
| Report Date: | 2024-04-30 |
| Date: | 2024-03-31 |
| Before After Market: | Before Market |
| Currency: | MXN |
| Eps Actual: | 42.17 |
| Report Date: | 2024-03-06 |
| Date: | 2023-12-31 |
| Before After Market: | Before Market |
| Currency: | MXN |
| Eps Actual: | 42.54 |
| Report Date: | 2023-11-02 |
| Date: | 2023-09-30 |
| Before After Market: | Before Market |
| Currency: | MXN |
| Eps Actual: | -1.08 |
| Report Date: | 2023-08-08 |
| Date: | 2023-06-30 |
| Before After Market: | Before Market |
| Currency: | MXN |
| Eps Actual: | 34.54 |
| Report Date: | 2023-04-27 |
| Date: | 2023-03-31 |
| Before After Market: | Before Market |
| Currency: | MXN |
| Eps Actual: | 27.77 |
| Report Date: | 2023-02-02 |
| Date: | 2022-12-31 |
| Before After Market: | Before Market |
| Currency: | MXN |
| Eps Actual: | 42.15 |
| Report Date: | 2022-11-01 |
| Date: | 2022-09-30 |
| Before After Market: | Before Market |
| Currency: | MXN |
| Eps Actual: | 32.51 |
| Report Date: | 2022-08-04 |
| Date: | 2022-06-30 |
| Before After Market: | Before Market |
| Currency: | MXN |
| Eps Actual: | 1.05 |
| Report Date: | 2022-03-31 |
| Date: | 2022-03-31 |
| Currency: | MXN |
| Eps Actual: | 43.04 |
| Report Date: | 2021-12-31 |
| Date: | 2021-12-31 |
| Currency: | MXN |
| Eps Actual: | 39.39 |
| Report Date: | 2021-09-30 |
| Date: | 2021-09-30 |
| Currency: | MXN |
| Eps Actual: | 24.41 |
| Report Date: | 2021-06-30 |
| Date: | 2021-06-30 |
| Currency: | MXN |
| Eps Actual: | 30.55 |
| Report Date: | 2021-03-31 |
| Date: | 2021-03-31 |
| Currency: | MXN |
| Eps Actual: | 30.23 |
| Report Date: | 2020-12-31 |
| Date: | 2020-12-31 |
| Currency: | MXN |
| Eps Actual: | 47.68 |
| Report Date: | 2020-09-30 |
| Date: | 2020-09-30 |
| Currency: | MXN |
| Eps Actual: | 29.28 |
| Report Date: | 2020-06-30 |
| Date: | 2020-06-30 |
| Currency: | MXN |
| Eps Actual: | 36.13 |
| Report Date: | 2020-03-31 |
| Date: | 2020-03-31 |
| Currency: | MXN |
| Eps Actual: | 32.02 |
| Report Date: | 2019-12-31 |
| Date: | 2019-12-31 |
| Currency: | MXN |
| Eps Actual: | 31.48 |
| Report Date: | 2019-09-30 |
| Date: | 2019-09-30 |
| Currency: | MXN |
| Eps Actual: | 26.52 |
| Report Date: | 2019-06-30 |
| Date: | 2019-06-30 |
| Currency: | MXN |
| Eps Actual: | 27.44 |
| Report Date: | 2019-03-31 |
| Date: | 2019-03-31 |
| Currency: | MXN |
| Eps Actual: | 82.77 |
| Report Date: | 2018-12-31 |
| Date: | 2018-12-31 |
| Currency: | MXN |
| Eps Actual: | 21.1 |
| Report Date: | 2018-09-30 |
| Date: | 2018-09-30 |
| Currency: | MXN |
| Eps Actual: | 21.23 |
| Report Date: | 2018-06-30 |
| Date: | 2018-06-30 |
| Currency: | MXN |
| Eps Actual: | -4.89 |
| Report Date: | 2018-03-31 |
| Date: | 2018-03-31 |
| Currency: | MXN |
| Eps Actual: | 21.72 |
| Report Date: | 2017-12-31 |
| Date: | 2017-12-31 |
| Currency: | MXN |
| Eps Actual: | -28.57 |
| Date: | 2024-09-30 |
| Eps Actual: | 98.78 |
| Date: | 2023-12-31 |
| Eps Actual: | 103.78 |
| Date: | 2022-12-31 |
| Eps Actual: | 118.77 |
| Date: | 2021-12-31 |
| Eps Actual: | 124.59 |
| Date: | 2020-12-31 |
| Eps Actual: | 145.12 |
| Date: | 2019-12-31 |
| Eps Actual: | 168.22 |
| Date: | 2018-12-31 |
| Eps Actual: | 59.15 |
| Date: | 2017-12-31 |
| Eps Actual: | -28.57 |